Ftse Mib
33.784,90
0,14%
DAX
17.975,01
0,39%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
0,00%
Bitcoin
59.162,35
0,07%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acumen Pharmaceuticals Inc (ABOS) Acumen Pharmaceuticals Inc (ABOS) Notizie

Acumen Pharmaceuticals Inc

ABOS
3,48
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:18:08
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/4/202414:00GLOBEAcumen Pharmaceuticals Presents First Comprehensive Clinical..
04/4/202414:00GLOBEAcumen Pharmaceuticals Collaborates with Lonza to Advance..
26/3/202412:00GLOBEAcumen Pharmaceuticals Reports Financial Results for the..
21/3/202413:00GLOBEAcumen Pharmaceuticals to Present Deeper Insights, Including..
19/3/202421:00GLOBEAcumen Pharmaceuticals to Report Fourth Quarter and Year-End..
12/3/202421:00GLOBEAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS..
08/3/202414:50GLOBEAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid..
21/2/202414:00GLOBEAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid..
14/2/202414:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202423:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/2/202413:16EDGAR2Form 8-K - Current report
01/2/202413:00GLOBEAcumen Pharmaceuticals Appoints Dr. James Doherty as..
20/1/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202422:36EDGAR2Form 144 - Report of proposed sale of securities
19/1/202422:35EDGAR2Form 144 - Report of proposed sale of securities
18/1/202422:29EDGAR2Form 144 - Report of proposed sale of securities
18/1/202422:28EDGAR2Form 144 - Report of proposed sale of securities
18/1/202422:27EDGAR2Form 144 - Report of proposed sale of securities
12/1/202414:42EDGAR2Form 8-K - Current report
08/1/202414:33EDGAR2Form 8-K - Current report
04/1/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15GLOBEAcumen Pharmaceuticals to Present at the 42nd Annual J.P...
04/12/202313:45EDGAR2Form 8-K - Current report
13/11/202323:10EDGAR2Form 8-K - Current report
13/11/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202313:20EDGAR2Form 8-K - Current report
13/11/202313:00GLOBEAcumen Pharmaceuticals Reports Third Quarter 2023 Financial..
07/11/202322:01GLOBEAcumen Pharmaceuticals to Participate in the Stifel..
06/11/202322:01GLOBEAcumen Pharmaceuticals to Report Third Quarter Financial..
06/11/202313:30GLOBEAcumen Pharmaceuticals, Inc. and Halozyme Enter Global..
02/11/202321:00GLOBEAcumen Pharmaceuticals to Participate in the UBS Biopharma..
27/10/202315:25GLOBEAcumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates..
04/10/202314:00GLOBEAcumen Pharmaceuticals to Present Deeper Insights from..
19/9/202322:00GLOBEAcumen Pharmaceuticals to Participate in the Cantor Global..
06/9/202322:00GLOBEAcumen Pharmaceuticals to Participate in the H.C. Wainwright..
19/8/202300:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202317:46EDGAR2Form 144 - Report of proposed sale of securities
08/8/202322:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:33EDGAR2Form 8-K - Current report
08/8/202313:00GLOBEAcumen Pharmaceuticals Reports Second Quarter 2023 Financial..
01/8/202322:00GLOBEAcumen Pharmaceuticals to Report Second Quarter Financial..
Apertura: Min: Max:
Chiusura: 3,48

La tua Cronologia

NASDAQ
ABOS
Acumen Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network